If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
88.00    1.90 (2.21%)
Bid:
88.90
Ask:
90.00
Spread: 1.10 (1.237%)
Market Cap: £144.27m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Disposal

11 Feb 2008 07:01

Yule Catto & Co PLC11 February 2008 Yule Catto & Co. plc Sale of James Robinson Yule Catto is an international producer of speciality chemicals, supplied toglobal customers for use in a wide range of industries includingpharmaceuticals, FMCG, paints and adhesives Yule Catto & Co plc ("Yule Catto" or the "Company") is pleased to announce thatit has exchanged conditional contracts with Vivimed Labs Limited ("Vivimed") forthe sale of the entire issued share capital of James Robinson Limited and otherassociated assets (together "James Robinson") for a consideration of $21.15million plus working capital of approximately $4.5 million. The considerationwill be paid as to $17.15 million plus the working capital amount in cash atcompletion and a further $4 million into escrow pending successful completion ofcertain product transfer arrangements. The completion of the sale is conditional on, amongst other things, Vivimedobtaining shareholder approval for the acquisition which is expected to beobtained by mid April 2008. The proceeds of the sale received by Yule Catto will be used to reduce theCompany's borrowings, and the transaction will be earnings accretive James Robinson carries on the development, manufacture and supply ofphotographic and photochromic chemicals and hair and other dyes. In the twelvemonths to 31 December 2006 it had sales of £17.8 million, an operating profit of£0.82 million and gross assets of £3.0 million. The James Robinson management team led by Dr Richard Smith will continue to runthe business. In addition, Yule Catto anticipates disposing of its interest in James RobinsonIndia (Private) Limited to its joint venture partner following the completion ofthe sale of James Robinson for a consideration of some $1.5 million. Adrian Whitfield, Chief Executive commented: "This sale is in line with YuleCatto's corporate strategy of delivering improved shareholder value from itsImpact Chemicals activities". 11 February 2008 ENQUIRIES: YULE CATTO Tel: 01279 442791Adrian Whitfield, Chief ExecutiveDavid Blackwood, Finance Director COLLEGE HILL Tel: 020 7457 2020Gareth DavidAnthony Parker This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
13th Aug 20124:32 pmRNSHolding(s) in Company
24th Jul 201210:23 amRNSHolding(s) in Company
20th Jul 20124:10 pmRNSHolding(s) in Company
16th Jul 20129:33 amRNSHolding(s) in Company
13th Jul 201210:38 amRNSChange of Auditor
6th Jul 20129:38 amRNSHolding(s) in Company
3rd Jul 20124:35 pmRNSHolding(s) in Company
2nd Jul 201212:46 pmRNSHolding(s) in Company
2nd Jul 201211:11 amRNSDirector/PDMR Shareholding
27th Jun 20127:00 amRNSTrading Statement
12th Jun 201210:30 amRNSDirector/PDMR Shareholding
8th Jun 20122:09 pmRNSDirector/PDMR Shareholding
7th Jun 20124:35 pmRNSDirector/PDMR Shareholding
25th May 201211:00 amRNSDirector Declaration
17th May 201212:22 pmRNSResult of AGM
17th May 201211:00 amRNSDirectorate Change
17th May 20127:00 amRNSInterim Management Statement
14th May 20123:47 pmRNSAnnual Information Update
17th Apr 20129:18 amRNSAnnual Financial Report
3rd Apr 20123:11 pmRNSDirector/PDMR Shareholding
2nd Apr 20127:00 amRNSMarl Site Operations
28th Mar 20125:15 pmRNSHolding(s) in Company
26th Mar 20127:00 amRNSDirector/PDMR Shareholding
23rd Mar 20127:00 amRNSDirectorate Change
19th Mar 20124:10 pmRNSDirector/PDMR Shareholding
16th Mar 20121:48 pmRNSDirector/PDMR Shareholding
16th Mar 20121:46 pmRNSDirector/PDMR Shareholding
16th Mar 20121:09 pmRNSDirector/PDMR Shareholding
14th Mar 20123:52 pmRNSDirector/PDMR Shareholding
14th Mar 20127:00 amRNSFinal Results
11th Jan 20127:00 amRNSTrading Update
9th Jan 201210:24 amRNSDirector/PDMR Shareholding
3rd Jan 20124:51 pmRNSDirector/PDMR Shareholding
1st Dec 20117:00 amRNSDisposal of Pharma Division
25th Nov 20117:00 amRNSDirectorate Change
10th Nov 20117:00 amRNSInterim Management Statement
1st Nov 20113:33 pmRNSHolding(s) in Company
31st Oct 201110:15 amRNSHolding(s) in Company
20th Oct 20112:42 pmRNSHolding(s) in Company
17th Oct 20118:20 amRNSAcquisition
28th Sep 20117:00 amRNSAnalyst and Investor Site Visit
5th Sep 20117:00 amRNSAppointment of Joint Broker
26th Aug 20117:00 amRNSHalf Yearly Report
10th Aug 20118:58 amRNSHolding(s) in Company
4th Aug 20119:02 amRNSBoard appointment
27th Jul 20111:12 pmRNSHolding(s) in Company
29th Jun 20114:46 pmRNSDirector/PDMR Shareholding
29th Jun 20114:44 pmRNSDirector/PDMR Shareholding
29th Jun 20112:17 pmRNSResult of EGM
22nd Jun 20113:59 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.